Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review

• Main Authors: Alix Démaris (Author), Ella S. K. Widigson (Author), Johan F. K. F. Ilvemark (Author), Casper Steenholdt (Author), Jakob B. Seidelin (Author), Wilhelm Huisinga (Author), Robin Michelet (Author), Linda B. S. Aulin (Author), Charlotte Kloft (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modellin...